

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1 NAME OF THE MEDICINAL PRODUCT**

BETESIL 2.250 mg medicated plaster.

### **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each 7.5 cm x 10 cm medicated plaster contains:  
2.250 mg of betamethasone valerate (corresponding to 1.845 mg of betamethasone).

Excipients with known effect:

Methyl parahydroxybenzoate (2.250 mg)

Propyl parahydroxybenzoate (1.125 mg)

For the full list of excipients, see section 6.1.

### **3 PHARMACEUTICAL FORM**

Medicated plaster.

Colourless plaster.

### **4 CLINICAL PARTICULARS**

#### **4.1 Therapeutic indications**

BETESIL is indicated in adults.

Treatment of inflammatory skin disorders which do not respond to treatment with less potent corticosteroids, such as eczema, lichenification, lichen planus, granuloma annulare, palmoplantar pustulosis and mycosis fungoides.

Due to its particular pharmaceutical form, BETESIL is suitable for mild to moderate chronic plaque psoriasis localized in difficult to treat areas (e.g. knees, elbows and anterior face of the tibia). Overall, the surface area treated with BETESIL should not exceed 5% of the body surface.

#### **4.2 Posology and method of administration**

Posology

Apply the medicated plaster to the skin area to be treated once a day. Do not exceed the maximum daily dose of six medicated plasters and the maximum treatment period of 30 days.

A new medicated plaster must be applied every 24 hours. It is also advisable to wait at least 30 minutes between one application and the next.

Once an appreciable improvement has been obtained, you can discontinue the application and possibly continue the treatment with a less potent corticosteroid.

#### *Paediatric population*

The safety and efficacy of BETESIL in children aged <18 years have not yet been established.

#### Method of administration

##### *Precautions to be taken before handling or administering the medicinal product*

Cleanse and carefully dry the area to be treated before each application so that the medicated plaster adheres well to the skin.

Open the sachet containing the medicated plaster and cut the plaster, if necessary, so that it fits the area to be treated. Peel off the protective film and apply the adhesive medicated part to the area concerned.

Any unused part of the plaster should be put back into the sachet so that it keeps and can be used at the next application (see section 6.3).

The medicated plaster must not be removed and reused.

Once the medicated plaster has been applied, the skin must not come in contact with water. It is advisable to take a bath or have a shower between applications.

Furthermore, if the medicated plaster is applied to particularly mobile parts (e.g. an elbow or knee) and its edges start to lift, it is advisable to apply the adhesive strips for securing dressings included in the medicinal product pack .

Never cover the medicated plaster completely with occlusive material or dressing.

### **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Cutaneous tuberculosis and viral skin infections (including vaccinia pustules, herpes zoster and herpes simplex). Exudative lesions and primary skin infections caused by fungi or bacteria (e.g. syphilitic skin lesions). Acne, acne rosacea, perioral dermatitis, skin ulcers, burns and frostbite.

Do not apply to face.

Do not use on patients under 18 years of age.

### **4.4 Special warnings and precautions for use**

In general, use of topical corticosteroids on large areas of the body and for prolonged periods, as well as the use of occlusive dressing can cause a temporary suppression of the hypothalamus-pituitary-adrenal axis, leading to secondary hypoadrenalism and adrenal hypercorticism, including the Cushing's syndrome. In these situations, treatment should be discontinued gradually and under strict control of a doctor due to the risk of acute adrenal insufficiency.

Sudden withdrawal of the treatment in psoriatic patients, may also lead to symptoms exacerbation or generalized pustular psoriasis.

Prolonged use of BETESIL in diffuse psoriasis (except for the treatment of isolated plaques) or diffuse eczema or application on lesions located in skin folds is not recommended, as these conditions may increase systemic absorption. The use of occlusive bandages, especially with plastic material, may increase this effect. The symptoms of this are: facial redness, weight changes (fat increase in body and face and loss in legs and arms), reddish streaks on stomach, headache, menstrual alterations, or an increase in unwanted face and body hair. In this regard, it is known that certain skin areas (face, eyelids, armpits, scalp and scrotum) absorb more easily than others (skin on the knees, elbows, palms of the hands and feet on soles).

Application of topical medicinal products, especially if prolonged, may give rise to hypersensitivity reaction. Skin atrophy has also been reported after three-week treatment periods.

In case of drug intolerance, for example if skin irritation or contact dermatitis occurs during treatment, it is necessary to stop the medicated plaster application and start suitable treatment (see section 4.8 “Undesirable effects”).

#### Topical steroid withdrawal syndrome

Long term use of topical steroids can result in the development of rebound flares after stopping treatment (topical steroid withdrawal syndrome).

A severe form of rebound flare can develop which takes the form of a dermatitis with intense redness, stinging and/or burning sensation, itch, skin peeling, oozing pustules that can spread beyond the initial treatment area.

It is more likely to occur when delicate skin sites such as the face and flexures are treated.

Should there be a reoccurrence of the condition within days to weeks after successful treatment a withdrawal reaction should be suspected. Reapplication should be made with caution: a specialist advise is recommended and other treatment options should be considered, if appropriate.

#### The label will state strong steroid.

#### Visual disturbance

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents

with symptoms such as blurred vision or other visual disturbances, the patient should be considered

for referral to an ophthalmologist for evaluation of possible causes which may include cataract,

glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported

after use of systemic and topical corticosteroids.

Corticosteroids may affect the results of the nitroblue tetrazolium test (NBT) for diagnosing bacterial infections by producing false negatives.

Medicinal products containing corticosteroids must be used with caution in patients with impaired immune system function (T-lymphocytes) or in those being treated with immunosuppressive therapy.

The product contains methyl parahydroxybenzoate and propyl parahydroxybenzoate, which may cause hypersensitivity reactions (possibly delayed).

#### **4.5 Interaction with other medicinal products and other forms of interaction**

No interaction studies have been performed.

At recommended doses, betamethasone valerate for topical use is not known to cause medically significant drug interactions. BETESIL did not show significant systemic absorption of betamethasone valerate.

#### **4.6 Fertility, pregnancy and lactation**

##### Pregnancy

There are no or limited amount of data from the use of betamethasone valerate in pregnant women.

Studies in animals have shown reproductive toxicity (see section 5.3).

Betesil is not recommended during pregnancy and in women of childbearing potential not using contraception.

##### Breast-feeding

Systemic corticosteroids are excreted in human milk.

It is unknown whether topical corticosteroids are excreted in human milk. Therefore topical corticosteroids should be used with caution also in nursing women and should not be applied to the breast.

#### **4.7 Effects on ability to drive and use machines**

BETESIL has no or negligible influence on the ability to drive and use machine.

#### **4.8 Undesirable effects**

The commonly reported adverse reactions are skin and subcutaneous tissue disorders, occurring in about 15% of patients treated. These undesirable effects are mainly due to the pharmacological effects of the medicinal product. They are local effects on the skin in the plaster application area. No systemic effects have been observed.

The following list of adverse reactions has been observed during controlled clinical trials.

Reported adverse reactions have been classified according to their frequency of observation using the following convention: very common ( $\geq 1/10$ ); common ( $\geq 1/100$ ,  $< 1/10$ ), uncommon ( $\geq 1/1,000$ ,  $< 1/100$ ); rare ( $\geq 1/10,000$ ,  $< 1/1,000$ ); very rare ( $< 1/10,000$ ) and not known when cannot be estimated from the available data.

All cases reported were found to be common. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Skin and subcutaneous tissue disorders	Common	Skin atrophy Telangiectasia Pustules Papules Furuncle Erythema Pruritus Skin erosion
	Not known	Withdrawal reactions (see section 4.4)

Other undesirable reactions not observed with BETESIL, but reported with topical corticosteroids are: contact dermatitis, hypersensitivity, oedema, purpura, striae atrophicae, dry skin, skin exfoliation, capillary fragility, skin irritation, hypertrichosis, hyperaesthesia, perioral dermatitis, burning or stretching sensation, folliculitis and skin hypopigmentation.

The use of topical corticosteroids on large areas of the body and for long periods, as well as the use of occlusive dressing can cause temporary suppression of the hypothalamus-pituitary-adrenal axis, leading to secondary hypoadrenalism and adrenal hypercorticism, including the Cushing's syndrome. In these situations, treatment should be discontinued gradually and under strict control of a doctor due to the risk of acute adrenal insufficiency.

Sudden withdrawal of the treatment in psoriatic patients may also lead to symptoms exacerbation or generalized pustular psoriasis (see section 4.4).

Hypersensitivity reactions to occlusive plastic material have been observed rarely.

Blurred vision may occur with a not known frequency (see also section 4.4)

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.

## **4.9 Overdose**

No case of overdose has been reported.

Due to the product characteristics and the route of administration, the occurrence of symptoms and signs of corticosteroid overdose is unlikely.

However, prolonged use of topical corticosteroids may cause the temporary suppression of the hypothalamus-pituitary-adrenal axis, leading to secondary hypoadrenalism. Adrenal hypercorticism symptoms spontaneously reverse and their treatment is symptomatic. If necessary, act to restore the

hydroelectrolytic balance. In the event of chronic toxicity, remove the corticosteroid from the organism slowly.

## **5 PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Corticosteroids, dermatological products: active corticosteroids (group III). ATC code: D07AC01.

Betamethasone valerate, a corticosteroid classified as potent, is active in the treatment of dermatosis, which responds to corticosteroids, due to its anti-inflammatory, antipruriginous and vasoconstrictor action.

### **5.2 Pharmacokinetic properties**

Corticosteroids applied to the skin are mainly held back by the stratum corneum, and only a small part reaches the dermis where they can be absorbed. Several factors may however favour greater absorption: the location and area of the skin to be treated, the type of lesion, the treatment duration and any occlusive dressing.

In a comparative study conducted in healthy volunteers in whom 6 medicated plasters a day or an equivalent amount of cream were applied during 21 consecutive days, the levels of betamethasone (BM) measured in blood after 4 and 21 days were measurable in 11 out of 17 of the medicated plaster group and in 4 out of 10 in the cream group (LOQ= 50pg/mL). When measurable, BM blood levels in the subjects receiving the medicated plasters appeared to be slightly higher as compared to what measured in those treated with the cream. However, this difference in terms of systemic exposure had no impact on the HPA-axis function, since both the cortisol 24-h profile and the cortisol increase following ACTH stimulation test, evaluated in these same subjects, were not modified after 4 or 21 days of treatment as compared to baseline. Betamethasone valerate is mainly metabolized in the liver, where it is inactivated. It is then conjugated in the liver and kidneys with sulphate or glucuronic acid and excreted in urine.

### **5.3 Preclinical safety data**

Topical administration of corticosteroids to pregnant laboratory animals may cause impairment of foetal maturation. There are no further significant data from preclinical trials, which may be relevant to physicians other than those already reported in other sections of the Summary of Product Characteristics.

## **6 PHARMACEUTICAL PARTICULARS**

## **6.1 List of excipients**

Plaster: unwoven cloth (polypropylene/polyethylene with or without rayon fibres) laminated with an ethylene-methyl methacrylate copolymer film.

Adhesive layer: sodium hyaluronate, 1,3-butylene glycol, glycerol, disodium edetate, tartaric acid, aluminium glycinate, polyacrylic acid, sodium polyacrylate, hydroxypropylcellulose, carmellose sodium, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), purified water.

Protective film: polyethylene terephthalate film.

## **6.2 Incompatibilities**

Not applicable.

## **6.3 Shelf life**

3 years.

After opening the sachet: 1 month.

## **6.4 Special precautions for storage**

Do not store above 25 °C.

Store the medicated plaster in its original sachet in order to preserve its integrity.

For storage conditions after first opening of the medicinal product, see section 6.3.

## **6.5 Nature and contents of container**

Boxes: 4 medicated plasters / 8 medicated plasters / 16 medicated plasters

Each medicated plaster is packed individually in a paper/polyethylene/aluminium/ethylene-methacrylic acid copolymer sachet.

Each box includes adhesive strips for securing dressings (medical device).

Not all pack sizes may be marketed

## **6.6 Special precautions for disposal**

Used medicated plasters must not be flushed down toilets.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7 MARKETING AUTHORISATION HOLDER**

IBSA Farmaceutici Italia S.r.l.

Via Martiri di Cefalonia 2, 26900

Lodi-Italy

**8     MARKETING AUTHORISATION NUMBER**

PL 21039 /0009

**9     DATE OF FIRST AUTHORISATION/RENEWAL OF THE  
AUTHORISATION**

Date of first authorization: 12 /03/2007

Date of latest renewal: 09/10/2011

**10    DATE OF REVISION OF THE TEXT**

29/08/2024